Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Gheyath Nasrallah and Hamad Al Romaihi.
Gheyath Nasrallah
Connection Strength
0.593
Hamad Al Romaihi
  1. Analytic comparison between three high-throughput commercial SARS-CoV-2 antibody assays reveals minor discrepancies in a high-incidence population. Sci Rep. 2021 06 04; 11(1):11837.
    View in: PubMed
    Score: 0.237
  2. Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses. J Travel Med. 2021 10 11; 28(7).
    View in: PubMed
    Score: 0.061
  3. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nat Med. 2021 09; 27(9):1614-1621.
    View in: PubMed
    Score: 0.060
  4. SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals. iScience. 2021 Jun 25; 24(6):102646.
    View in: PubMed
    Score: 0.059
  5. SARS-CoV-2 Infection Is at Herd Immunity in the Majority Segment of the Population of Qatar. Open Forum Infect Dis. 2021 Aug; 8(8):ofab221.
    View in: PubMed
    Score: 0.059
  6. SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy. EClinicalMedicine. 2021 May; 35:100861.
    View in: PubMed
    Score: 0.059
  7. Epidemiological impact of prioritising SARS-CoV-2 vaccination by antibody status: mathematical modelling analyses. BMJ Innov. 2021 Apr; 7(2):327-336.
    View in: PubMed
    Score: 0.059
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.